Adjunct Professor Tom Duley is a partner in King & Spalding’s Corporate Practice Group. He concentrates his practice on technology transactions for life sciences clients, including collaboration agreements between biotechnology and pharmaceutical companies, licensing agreements with commercial businesses and academic institutions, supply and manufacturing agreements, distribution agreements and asset purchases and sales involving drug products and manufacturing facilities.
Professor Duley has worked with clients throughout the corporate lifecycle, from startup entities obtaining their first university in-license to large public corporations restructuring their product holdings. He was previously Senior Corporate Counsel of PDL BioPharma, Inc. (NASDAQ: PDLI), when it was a fully integrated biopharmaceutical company. He later advised PDL BioPharma on its spin-out of Facet Biotech. Professor Duley has been featured as a Life Sciences Star within the inaugural edition of LMG Life Sciences 2012 and again in the 2013 edition. He also served on the Board of Directors of Parnell Veterinary Pharmaceutical Holdings, Ltd. (NASDAQ: PARN), a fully integrated animal health company located in Overland Park, Kansas, U.S.A, and Alexandria, NSW, Australia.